Brokerage Firm Rating Update on Merck & Company (MRK)

Merck & Company (MRK) : Zacks Investment Research ranks Merck & Company (MRK) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 7 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 2.08, which indicates as a Buy.

Merck & Company (MRK) stock is expected to deviate a maximum of $7.2 from the average target price of $65.58 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $80 and the most muted being $57.


Company shares have received an average consensus rating of Hold for the current week Also, Equity Analysts at the Brokerage Firm, UBS, maintains their rating on the shares of Merck & Company (NYSE:MRK). UBS has a Buy rating on the shares. As per the latest research report, the brokerage house raises the price target to $70 per share from a prior target of $62. The rating by the firm was issued on August 19, 2016.

Merck & Company (NYSE:MRK): stock was range-bound between the intraday low of $62.595 and the intraday high of $63.49 after having opened at $63.31 on Wednesdays session. The stock finally closed in the red at $63.31, a loss of -0.59%. The stock remained in the red for the whole trading day. The total traded volume was 8,668,143 shares. The stock failed to cross $63.49 in Wednesdays trading. The stocks closing price on Thursday was $63.24.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.